| Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection (NCT00111397) | National Institute of Allergy and Infectious Diseases (NIAID) | 2005-05-13 |
| A Randomized, Double-Blinded, Placebo-Controlled, Phase II Inhaled Interferon Gamma-1b and Antimycobacterials to Treat Pulmonary Mycobacterium Avium Complex Infections (NCT00021567) | National Institute of Allergy and Infectious Diseases (NIAID) | 2001-07-01 |
| Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy (NCT00000883) | National Institute of Allergy and Infectious Diseases (NIAID) | 1997-10-01 |
| Phase II Study of Amithiozone (Thiacetazone) for Patients With Mycobacterium Avium Complex Pulmonary Disease (NCT00004689) | National Jewish Health | 1991-01-01 |
| An Open-Label Study of the Use of Azithromycin in Patients With Symptomatic Disseminated Mycobacterium Avium-Intracellulare Complex (MAC) Infection Failing Current Therapy (NCT00002089) | Pfizer | |
| A Randomized Study of Daily and Intermittent Prophylactic Regimens for the Prevention of Disseminated Mycobacterium Avium Complex (MAC) and Fungal Infections in HIV-Infected Patients (NCT00002122) | Pfizer | |
| A Randomized, Double-Blind, Comparative Study of Azithromycin Versus Clarithromycin in Combination With Ethambutol for the Treatment of Disseminated Mycobacterium Avium Complex (MAC) Infection in AIDs Patients (NCT00002140) | Pfizer | |
| A Study to Examine the Effects of Stopping Preventive Therapy for Disseminated Mycobacterium Avium Complex (DMAC) in HIV-Positive Patients (NCT00000907) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluation of the Therapeutic Benefit of r-metHuIFN- Gamma in AIDS Patients With Disseminated Mycobacterium Avium-Intracellulare (MAI) Infection: A Multi-Centered Pilot Study (NCT00002037) | Amgen | |
| A Study to Learn More About MAC Disease and the Use of Anti-HIV Drugs in Patients With Advanced HIV Infection (NCT00000895) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals. (NCT00000641) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Phase II Safety and Efficacy Study of Clarithromycin in the Treatment of Disseminated M. Avium Complex (MAC) Infections in Patients With AIDS (NCT00000644) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Rifabutin, Used Alone or With Ethambutol in the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in Patients With AIDS (NCT00002343) | Pharmacia | |
| A Double-Blind Randomized Clinical Trial of a Rifabutin Regimen in the Treatment of Mycobacterium-Avium Complex (MAC) Bacteremia in Patients With AIDS (NCT00001995) | Pharmacia | |
| Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial (NCT00002032) | Pharmacia | |
| Placebo-Controlled Trial of Safety and Efficacy of Thalidomide in Patients With Infections Due to Mycobacterium and/or HIV (NCT00002104) | Aaron Diamond AIDS Research Center | |
| The Safety and Effectiveness of Clarithromycin and Rifabutin Used Alone or in Combination to Prevent Mycobacterium Avium Complex (MAC) or Disseminated MAC Disease in HIV-Infected Patients (NCT00001030) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Three-Arm Comparative Trial for the Treatment of MAC Bacteremia in AIDS: A Clarithromycin/Ethambutol Regimen Containing Rifabutin (450 Mg) or Rifabutin (300 Mg) or Placebo (NCT00002101) | Pharmacia | |
| A Comparison of Three Drug Combinations Containing Clarithromycin in the Treatment of Mycobacterium Avium Complex (MAC) Disease in Patients With AIDS (NCT00001058) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Study of Four Different Treatment Approaches for Patients Who Have Mycobacterium Avium Complex Disease (MAC) Plus AIDS (NCT00001047) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Azithromycin in the Prevention of Mycobacterium Avium Complex Disease (MAC) in HIV-Infected Patients (NCT00002309) | Pfizer | |
| Rifabutin Therapy for the Prevention of Mycobacterium Avium Complex (MAC) Bacteremia in AIDS Patients With CD4 Counts = or < 200: A Double-Blind, Placebo-Controlled Trial (NCT00002267) | Pharmacia | |
| A Study to Evaluate the Effects of Azithromycin on MAC Disease Prevention in HIV-Positive Patients (NCT00000947) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Study of Viracept in AIDS Patients With Mycobacterium Avium Complex Disease (MAC) (NCT00002170) | Agouron Pharmaceuticals | |
| The Effects of Treatment for Mycobacterium Avium Complex (MAC) on the Cells of HIV-Infected Patients (NCT00000860) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| Evaluation of Treatment for Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients (NCT00001039) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| The Safety and Effectiveness of Rifabutin, Combined With Clarithromycin or Azithromycin, in HIV-Infected Patients (NCT00001023) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| An Open, Multicenter, Randomized, Dose-Ranging Study of Azithromycin in the Treatment of Disseminated Mycobacterium Avium-Intracellulare Complex Infection (MAC) in Patients With Acquired Immune Deficiency Syndrome (AIDS) (NCT00002090) | Pfizer | |
| Effects of MAC Preventive Therapy on Disease-Causing Bacteria in HIV-Infected Patients: A Substudy of CPCRA 048 (NCT00000933) | National Institute of Allergy and Infectious Diseases (NIAID) | |
| A Randomized Controlled Prophylactic Study of Clofazimine To Prevent Mycobacterium Avium Complex Infection in HIV Disease (NCT00002058) | University of California, San Francisco | |